Ciprofloxacin Special Drug Use Investigation - To Investigate the Safety and Efficacy in Patients With Ciprofloxacin iv Administration Without Dilution
Ciprofloxacin Special Drug Use Investigation - To Investigate the Safety and Efficacy in Patients With Ciprofloxacin iv Administration Without Dilution
This study is a post-marketing surveillance in Japan to investigate the safety especially
 focusing on injection site adverse events and efficacy in patients with Ciprofloxacin iv
 administration without dilution in the daily practice.It is a local prospective and
 observational study of patients who have received Ciproxan intravenously for sepsis,
 secondary skin infections followed by superficial burn, post-surgical or post-traumatic,
 pneumonia, peritonitis, cholecystitis, cholangitis, anthrax. A total of 500 patients are to
 be enrolled and assessed during the period of treatment with Ciproxan.
Inclusion Criteria:

 -  - The mentioned bellow patients caused by the following bacteria which are sensitive
 to this drug: Indicated microorganisms:Staphylococcus, Enterococcus, Bacillus
 anthracis, Escherichia coli, Klebsiella , Enterobacter, Pseudomonas aeruginosa,
 Legionella. Indications: Sepsis, Secondary skin infections (superficial burn,
 operative wounds, trauma), Pneumonia, Peritonitis, Cholecystitis, Cholangitis, Anthrax

 -  The patients treated with this drug without dilution due to strict restriction of
 fluid intake.

 -  In hospitalized patients who retain consciousness ,and at the same time who are able
 to report (such as vascular pain) side effects..

 Exclusion Criteria:

 -  Patients who are contraindicated based on the product label.